AMN107 (nilotinib)

nilotinib · Novartis Pharmaceuticals

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AMN107 (nilotinib), covering 2017-02-23 to 2017-02-23. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib [Phase 2]

See pricing